Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection

program collaborators for Environmental influences on Child Health Outcomes

doi:10.1164/rccm.202010-3753oc

Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection

program collaborators for Environmental influences on Child Health Outcomes

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

RATIONALE: Rhinovirus C (RV-C) can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing.

OBJECTIVES: To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses.

METHODS: Longitudinal data from the Childhood Origins of ASThma (COAST) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for rhinovirus A (RV-A) and RV-C (3 types each) were determined using a novel polymerase chain reaction-based assay. We pooled data from 14 study cohorts in the United States, Finland, and Australia and used mixed-effects logistic regression to identify factors related to the proportion of RV-C versus RV-A detection.

MEASUREMENTS AND MAIN RESULTS: In COAST, RV-A and RV-C infections were similarly common in infancy, while RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (p<0.001, chi-square) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5%-27%) at age 2 years, but by age 16, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A, p<0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (p<0.0001), CDHR3 genotype (p<0.05), and wheezing illnesses (p<0.05). Furthermore, certain RV types (e.g., C2, C11, A78, A12) were consistently more virulent and prevalent over time.

DISCUSSION: Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.

Original language	English (US)
Pages (from-to)	822-830
Number of pages	9
Journal	American journal of respiratory and critical care medicine
Volume	203
Issue number	7
Early online date	Dec 24 2020
DOIs	https://doi.org/10.1164/rccm.202010-3753oc
State	Published - Apr 1 2021

Bibliographical note

Funding Information:
Supported by the Environmental Influences on Child Health Outcomes program, Office of The Director, NIH, under award numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (Person-Reported Outcome [PRO] Core), UG3/UH3 OD023282, and UG3/UH3 OD-023253; NIH grants R01AI148707, P01 HL070831, UM1 AI114271, R01 AI-114552, R01 AI-127507, U19 AI095227, UL1 RR024975, and R01-AI097172; the Sigrid Juselius Foundation, Helsinki, Finland; National Health and Medical Research Council grants 211912, 458513; and by grants APP1045760, APP1087700, APP1129996, APP1147630. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other funding agencies.

Publisher Copyright:
© 2021 by the American Thoracic Society.

Keywords

CDHR3
Epidemiology
Genetics
Rhinovirus
Wheezing
Age Factors
Rhinovirus/genetics
Humans
Australia/epidemiology
Child, Preschool
Infant
Male
Genetic Variation
Picornaviridae Infections/epidemiology
United States/epidemiology
Female
Child
Infant, Newborn
Disease Susceptibility
Respiratory Sounds/physiopathology
Genotype
Antibodies, Neutralizing/blood
Finland/epidemiology
Adolescent
Asthma/epidemiology
Longitudinal Studies
Cohort Studies

PubMed: MeSH publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Journal Article
Research Support, N.I.H., Extramural
Comparative Study

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1164/rccm.202010-3753oc

Find It

Find It at U of M Libraries

Cite this

@article{c4f7020838624eeb90cc2f99411c1d7d,

title = "Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection",

abstract = "RATIONALE: Rhinovirus C (RV-C) can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing.OBJECTIVES: To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses.METHODS: Longitudinal data from the Childhood Origins of ASThma (COAST) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for rhinovirus A (RV-A) and RV-C (3 types each) were determined using a novel polymerase chain reaction-based assay. We pooled data from 14 study cohorts in the United States, Finland, and Australia and used mixed-effects logistic regression to identify factors related to the proportion of RV-C versus RV-A detection.MEASUREMENTS AND MAIN RESULTS: In COAST, RV-A and RV-C infections were similarly common in infancy, while RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (p<0.001, chi-square) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5%-27%) at age 2 years, but by age 16, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A, p<0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (p<0.0001), CDHR3 genotype (p<0.05), and wheezing illnesses (p<0.05). Furthermore, certain RV types (e.g., C2, C11, A78, A12) were consistently more virulent and prevalent over time.DISCUSSION: Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.",

keywords = "CDHR3, Epidemiology, Genetics, Rhinovirus, Wheezing, Age Factors, Rhinovirus/genetics, Humans, Australia/epidemiology, Child, Preschool, Infant, Male, Genetic Variation, Picornaviridae Infections/epidemiology, United States/epidemiology, Female, Child, Infant, Newborn, Disease Susceptibility, Respiratory Sounds/physiopathology, Genotype, Antibodies, Neutralizing/blood, Finland/epidemiology, Adolescent, Asthma/epidemiology, Longitudinal Studies, Cohort Studies",

author = "{program collaborators for Environmental influences on Child Health Outcomes} and Timothy Choi and Mark Devries and Len Bacharier and William Busse and Camargo, {Carlos A} and Robyn Cohen and Demuri, {Gregory P} and Evans, {Michael D} and Fitzpatrick, {Anne M} and Gergen, {Peter J} and Kristine Grindle and Rebecca Gruchalla and Tina Hartert and Kohei Hasegawa and {Khurana Hershey}, {Gurjit K} and Patrick Holt and Kiara Homil and Tuomas Jartti and Meyer Kattan and Carolyn Kercsmar and Haejin Kim and Laing, {Ingrid A} and Petra LeBeau and Lee, {Kristine E} and {Le Sou{\"e}f}, {Peter N} and Andrew Liu and Mauger, {David T} and Carole Ober and Tressa Pappas and Patel, {Shilpa J} and Wanda Phipatanakul and Jacqueline Pongracic and Christine Seroogy and Sly, {Peter D} and Christopher Tisler and Wald, {Ellen R} and Robert Wood and Ronald Gangnon and Jackson, {Daniel J} and Lemanske, {Robert F} and Gern, {James E} and Bochkov, {Yury A}",

note = "Funding Information: Supported by the Environmental Influences on Child Health Outcomes program, Office of The Director, NIH, under award numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (Person-Reported Outcome [PRO] Core), UG3/UH3 OD023282, and UG3/UH3 OD-023253; NIH grants R01AI148707, P01 HL070831, UM1 AI114271, R01 AI-114552, R01 AI-127507, U19 AI095227, UL1 RR024975, and R01-AI097172; the Sigrid Juselius Foundation, Helsinki, Finland; National Health and Medical Research Council grants 211912, 458513; and by grants APP1045760, APP1087700, APP1129996, APP1147630. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other funding agencies. Publisher Copyright: {\textcopyright} 2021 by the American Thoracic Society.",

year = "2021",

month = apr,

day = "1",

doi = "10.1164/rccm.202010-3753oc",

language = "English (US)",

volume = "203",

pages = "822--830",

journal = "American Review of Respiratory Disease",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "7",

}

TY - JOUR

T1 - Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection

AU - program collaborators for Environmental influences on Child Health Outcomes

AU - Choi, Timothy

AU - Devries, Mark

AU - Bacharier, Len

AU - Busse, William

AU - Camargo, Carlos A

AU - Cohen, Robyn

AU - Demuri, Gregory P

AU - Evans, Michael D

AU - Fitzpatrick, Anne M

AU - Gergen, Peter J

AU - Grindle, Kristine

AU - Gruchalla, Rebecca

AU - Hartert, Tina

AU - Hasegawa, Kohei

AU - Khurana Hershey, Gurjit K

AU - Holt, Patrick

AU - Homil, Kiara

AU - Jartti, Tuomas

AU - Kattan, Meyer

AU - Kercsmar, Carolyn

AU - Kim, Haejin

AU - Laing, Ingrid A

AU - LeBeau, Petra

AU - Lee, Kristine E

AU - Le Souëf, Peter N

AU - Liu, Andrew

AU - Mauger, David T

AU - Ober, Carole

AU - Pappas, Tressa

AU - Patel, Shilpa J

AU - Phipatanakul, Wanda

AU - Pongracic, Jacqueline

AU - Seroogy, Christine

AU - Sly, Peter D

AU - Tisler, Christopher

AU - Wald, Ellen R

AU - Wood, Robert

AU - Gangnon, Ronald

AU - Jackson, Daniel J

AU - Lemanske, Robert F

AU - Gern, James E

AU - Bochkov, Yury A

N1 - Funding Information: Supported by the Environmental Influences on Child Health Outcomes program, Office of The Director, NIH, under award numbers U2COD023375 (Coordinating Center), U24OD023382 (Data Analysis Center), U24OD023319 (Person-Reported Outcome [PRO] Core), UG3/UH3 OD023282, and UG3/UH3 OD-023253; NIH grants R01AI148707, P01 HL070831, UM1 AI114271, R01 AI-114552, R01 AI-127507, U19 AI095227, UL1 RR024975, and R01-AI097172; the Sigrid Juselius Foundation, Helsinki, Finland; National Health and Medical Research Council grants 211912, 458513; and by grants APP1045760, APP1087700, APP1129996, APP1147630. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other funding agencies. Publisher Copyright: © 2021 by the American Thoracic Society.

PY - 2021/4/1

Y1 - 2021/4/1

N2 - RATIONALE: Rhinovirus C (RV-C) can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing.OBJECTIVES: To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses.METHODS: Longitudinal data from the Childhood Origins of ASThma (COAST) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for rhinovirus A (RV-A) and RV-C (3 types each) were determined using a novel polymerase chain reaction-based assay. We pooled data from 14 study cohorts in the United States, Finland, and Australia and used mixed-effects logistic regression to identify factors related to the proportion of RV-C versus RV-A detection.MEASUREMENTS AND MAIN RESULTS: In COAST, RV-A and RV-C infections were similarly common in infancy, while RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (p<0.001, chi-square) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5%-27%) at age 2 years, but by age 16, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A, p<0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (p<0.0001), CDHR3 genotype (p<0.05), and wheezing illnesses (p<0.05). Furthermore, certain RV types (e.g., C2, C11, A78, A12) were consistently more virulent and prevalent over time.DISCUSSION: Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.

AB - RATIONALE: Rhinovirus C (RV-C) can cause asymptomatic infection and respiratory illnesses ranging from the common cold to severe wheezing.OBJECTIVES: To identify how age and other individual-level factors are associated with susceptibility to RV-C illnesses.METHODS: Longitudinal data from the Childhood Origins of ASThma (COAST) birth cohort study were analyzed to determine relationships between age and RV-C infections. Neutralizing antibodies specific for rhinovirus A (RV-A) and RV-C (3 types each) were determined using a novel polymerase chain reaction-based assay. We pooled data from 14 study cohorts in the United States, Finland, and Australia and used mixed-effects logistic regression to identify factors related to the proportion of RV-C versus RV-A detection.MEASUREMENTS AND MAIN RESULTS: In COAST, RV-A and RV-C infections were similarly common in infancy, while RV-C was detected much less often than RV-A during both respiratory illnesses and scheduled surveillance visits (p<0.001, chi-square) in older children. The prevalence of neutralizing antibodies to RV-A or RV-C types was low (5%-27%) at age 2 years, but by age 16, RV-C seropositivity was more prevalent (78% vs. 18% for RV-A, p<0.0001). In the pooled analysis, the RV-C to RV-A detection ratio during illnesses was significantly related to age (p<0.0001), CDHR3 genotype (p<0.05), and wheezing illnesses (p<0.05). Furthermore, certain RV types (e.g., C2, C11, A78, A12) were consistently more virulent and prevalent over time.DISCUSSION: Knowledge of prevalent RV types, antibody responses, and populations at risk based on age and genetics may guide the development of vaccines or other novel therapies against this important respiratory pathogen.

KW - CDHR3

KW - Epidemiology

KW - Genetics

KW - Rhinovirus

KW - Wheezing

KW - Age Factors

KW - Rhinovirus/genetics

KW - Humans

KW - Australia/epidemiology

KW - Child, Preschool

KW - Infant

KW - Male

KW - Genetic Variation

KW - Picornaviridae Infections/epidemiology

KW - United States/epidemiology

KW - Female

KW - Child

KW - Infant, Newborn

KW - Disease Susceptibility

KW - Respiratory Sounds/physiopathology

KW - Genotype

KW - Antibodies, Neutralizing/blood

KW - Finland/epidemiology

KW - Adolescent

KW - Asthma/epidemiology

KW - Longitudinal Studies

KW - Cohort Studies

UR - http://www.scopus.com/inward/record.url?scp=85103803232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103803232&partnerID=8YFLogxK

U2 - 10.1164/rccm.202010-3753oc

DO - 10.1164/rccm.202010-3753oc

M3 - Article

C2 - 33357024

SN - 1073-449X

VL - 203

SP - 822

EP - 830

JO - American Review of Respiratory Disease

JF - American Review of Respiratory Disease

IS - 7

ER -

Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this